Dejar un mensaje

Si está interesado en nuestros productos y desea conocer más detalles, deje un mensaje aquí, le responderemos lo antes posible.

Hogar reactivos OEM

Cardiovascular Panel: CK-MB OEM kit Adopting Chemiluminescence assay platforms

Name: Cardiovascular Panel: CK-MB OEM kit Adopting Chemiluminescence assay platforms
Availability: InStock

Creatine Kinase-MB (CK-MB) is applied for auxiliary diagnosis of acute myocardial infarction and assessment of myocardial injury in patients with suspected cardiovascular diseases.

CK-MB OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific antibodies target CK-MB epitopes to capture plasma CK-MB, delivering high sensitivity and specificity. Calibrated with high-purity recombinant CK-MB, the assay provides accurate and stable quantitative results. Serving as a classic biomarker for acute myocardial infarction diagnosis, it supports early identification and dynamic monitoring of myocardial damage for clinical auxiliary diagnosis.

Creatine Kinase-MB (CK-MB) is an isoenzyme of creatine kinase (CK) formed via post-translational modification. It is predominantly located in cardiomyocytes, with minor distribution in skeletal muscle, intestine, tongue, prostate and uterus. As a key enzyme in myocardial energy metabolism, CK-MB consists of M and B subunits (M for muscle, B for brain), accounting for 15%–30% of total CK activity. As a critical diagnostic biomarker, CK-MB has gained increasing attention, especially in cardiovascular disorders. Studies verify that both CK-MB mass and activity show good sensitivity for cardiac disease diagnosis. CK-MB mass demonstrates superior anti-interference stability compared with CK-MB activity measurement.

★Bulk reagents are available with matching raw materials.

Marca :
QYM,SURFTECH
Artículo n.° :
CKMB-1
Pedido (MOQ) :
On request
Pago :
T/T
Origen del producto :
China
Color :
R1 should be a colorless to pale yellow transparent liquid; R2 should be a milky white suspension.
Puerto de embarque :
Hefei or other ports
Plazo de entrega :
On request
Peso :
On request

Pregunte ahora

CATEGORÍAS DE PRODUCTOS

¿Cómo podemos ayudarte?

Puede contactarnos de la forma que le resulte más cómoda. Estamos disponibles 24/7 por correo electrónico o teléfono.

CONTÁCTENOS

Nuevos productos

Detalles del producto

CK-MB OEM reagent

Product Specifications

Product Name	CK-MB OEM reagent (chemiluminescence platforms)
Application:	It is applied for auxiliary diagnosis of acute myocardial infarction and assessment of myocardial injury in patients with suspected cardiovascular diseases.
Assay Principle:	Two-antibody sandwich immunoassay
Sample Type:	Serum / Plasma
Calibrator Component:	Recombinant CK-MB
Analytical Sensitivity	0.1 ng/mL
Linear Range:	0.1–300 ng/mL
Precision:	Intra-assay ≤5%; Inter-assay ≤8%
Method Comparison:	r＞0.975 vs. Roche
Incubation Time	10 min
Calibration Interval	28 days
Interfering Substances	Bilirubin <34 mg/dL; Hemoglobin <1.5 g/dL; Lipids <1500 mg/dL
Hook Effect Concentration	5000 ng/mL
Package Size	on request
Storage/Shipping	Store sealed and protected from light at 2 °C to 8 °C
Shelf Life	12 months

Product Advantages

1.Superior precision, CV ≈ 1%.

2.Sensitivity 0.1 ng/mL, comparable to global top standards.

3.High correlation with Roche, R² > 0.975.

4.Linear correlation coefficient >0.99 across 0.1–300 ng/mL, world-class performance.

Batch precision test Sensitivity Analysis Linear Range Validation

Application Scenarios

Creatine Kinase-MB (CK-MB) is applied for auxiliary diagnosis of acute myocardial infarction and assessment of myocardial injury in patients with suspected cardiovascular diseases.

--------------占位---------------

FAQ

Is the OEM kit based on double-antibody sandwich Mass assay or Immunoinhibition Activity assay?

It uses a sandwich immuno-mass assay (CLIA), providing superior specificity and precision by measuring CK-MB protein concentration (ng/mL) directly without interference from CK-MM or CK-BB.

How well does it correlate with clinical reference systems ?

High correlation with Roche ( $R^2 > 0.95$ ) across clinical serum and plasma panels, ensuring consistent diagnostic cut-offs for early AMI identification and re-infarction monitoring.